0001104659-24-065645.txt : 20240528
0001104659-24-065645.hdr.sgml : 20240528
20240528170138
ACCESSION NUMBER: 0001104659-24-065645
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240523
FILED AS OF DATE: 20240528
DATE AS OF CHANGE: 20240528
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nayak Sanjay
CENTRAL INDEX KEY: 0002012715
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36554
FILM NUMBER: 24992869
MAIL ADDRESS:
STREET 1: C/O OCULAR THERAPEUTIX, INC.
STREET 2: 24 CROSBY DRIVE
CITY: BEDFORD
STATE: MA
ZIP: 01730
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: OCULAR THERAPEUTIX, INC
CENTRAL INDEX KEY: 0001393434
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 15 CROSBY DRIVE
CITY: BEDFORD
STATE: MA
ZIP: 01730
BUSINESS PHONE: 781-357-4000
MAIL ADDRESS:
STREET 1: 15 CROSBY DRIVE
CITY: BEDFORD
STATE: MA
ZIP: 01730
FORMER COMPANY:
FORMER CONFORMED NAME: I-THERAPEUTIX INC
DATE OF NAME CHANGE: 20070315
4
1
tm2415610-2_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-05-23
0
0001393434
OCULAR THERAPEUTIX, INC
OCUL
0002012715
Nayak Sanjay
C/O OCULAR THERAPEUTIX, INC.
15 CROSBY DRIVE
BEDFORD
MA
01730
0
1
0
0
Chief Strategy Officer
1
Common Stock
2024-05-23
4
S
0
2274
5.84
D
178026
D
Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on May 22, 2024. The sales do not represent a discretionary trade by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.77 to $5.92, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
/s/ Donald Notman, Attorney-in-Fact for Sanjay Nayak
2024-05-28